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INTRODUCTION
The incidence of AML rises sharply in adults over the 
age of 50. Although advances in chemotherapy and 
stem cell transplantation (SCT) have improved the 
outcome of children and younger adults there have 
only been modest improvements in the survival of 
older patients in the past three decades 1-3. More ef-
fective anti-leukemic therapies are therefore urgently 
required in this sizeable patient population. 
Allogeneic transplantation using a myeloablative 
conditioning regimen has been shown to represent the 
most effective form of anti-leukaemic therapy in adult 
AML and improves both disease free survival (DFS) 
and overall survival (OS) compared with standard 
chemotherapy in younger patients but is contra-indi-
cated in older patients because of excessive transplant 
toxicity4,5. The advent of reduced intensity condition-
ing (RIC) regimens has led to the possibility that it 
may be possible to extend the curative potential of al-
logeneic transplantation to older patients with AML 
in whom it was previously contra-indicated on the 
grounds of age or co-morbidity6-8. Whilst it is incon-
testable that RIC regimens have reduced the immedi-
ate toxicity of allografting there remains a significant 
risk of acute and chronic graft-versus-host disease 
(GVHD) in patients transplanted with a T replete stem 
cell inoculum. As a result GVHD now represents the 
major cause of morbidity and mortality after a RIC 
transplant and significantly limits both the potential 
for post-transplant immunotherapy as well as the pos-
sibility of transplanting frailer patients6,7,9-11. It is now 
clear that administration of T cell depleting antibodies 
such alemtuzumab or anti-thymocyte globulin, reduc-
es the risk of both acute and chronic GVHD without 
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compromising engraftment in patients transplanted 
using a reduced intensity regimen12-15. However 
there remain concerns that depletion of T cells from 
the stem cell inoculum may compromise the ability 
of RIC allografts to deliver durable remissions14,16,17. 
In order to define more clearly the potential role of 
alemtuzumab based reduced intensity regimens in the 
management of AML we have analyzed the factors 
determining survival in 168 patients transplanted over 
a ten year period.
PATIENTS AND METHODS
Patients
67 patients with AML were transplanted using a flu-
darabine/melphalan/alemtuzumab RIC regimen from 
February 1997- June 2007. Patients whose outcome 
with chemotherapy was deemed to be poor and in 
whom a myeloablative conditioning was contra-indi-
cated on the grounds of age, co-morbidity or patient 
choice were eligible. The median age was 54 years 
(range 18-71 years). 35 patients were 60 years of age 
or over. 37 patients received an allograft from an un-
related donor and 30 from a matched sibling donor. 
50 patients were in remission at the time of transplant 
(CR1 = 32, CR2/CR3 or beyond = 17). 18 patients 
had relapsed or refractory disease. The results of pre-
sentation cytogenetic analysis were available for 64 
patients and risk stratification was performed using 
MRC criteria18. 24 patients were classified as interme-
diate risk at diagnosis. 16 patients had adverse risk 
cytogenetics. 
Transplant details and monitoring:
The conditioning regimen incorporated fludarabine 
(30mg/m2/day for 5 days) melphalan (140mg/m2 for 
1 day) and alemtuzumab (10-20 mg/day for 5 days) 
as previously reported12,13. Cyclosporin was used 
as GvHD prophylaxis at an initial dose of 5 mg/kg/
day with the aim of discontinuing administration at 
day 90. Patients were enrolled after written informed 
consent had been obtained. Unrelated donor selec-
tion was performed according to published criteria 
and involved molecular typing for Class 1 (HLA-A 
and HLA-B, HLA-C) and Class II (DRB1 and DQB1) 
alleles. 6 patients underwent transplantation from an 
unrelated donor with an antigenic mismatch at Class 
I or II alleles. There was no evidence to suggest that 
patients receiving mismatched unrelated donor grafts 
constituted a demographically distinct population. 
Unrelated donors gave written consent through the 
current accepted standards and procedures of the rel-
evant registry. The source of stem cells was peripheral 
blood (PBSC), collected after treating donors with 
granulocyte-colony stimulating factor (10 µg/kg/d for 
four days) in 62 patients, or bone marrow mononu-
clear cells in 5 (3 VUD, 2 sibling). The median CD34+ 
cell dose in patients allografted with PBSC was 5.3 
x 106 CD34+ cells/kg (range 1.3-15.8). The median 
mononuclear cell dose in recipients of bone marrow 
cells was 4.3 x 108 mononuclear cells/kg (range 0.7-
20.1). 
Anti-microbial prophylaxis was determined by 
local protocols but all patients received prophylactic 
trimethoprim/sulfamethoxazole or nebulised pentam-
idine as prophylaxis against Pneumocystis jirovecii 
pneumonia. If either patient or donor were seroposi-
tive for cytomegalovirus (CMV) pre-transplant, plas-
ma specimens were monitored weekly for evidence of 
CMV re-activation by PCR analysis post-transplant 
until 100 days post-transplant. Patients with evidence 
of CMV re-activation received pre-emptive therapy 
with ganciclovir. 
Chimerism studies were performed on whole 
blood or bone marrow and a T cell purified subfrac-
tion at 3 months post-transplant in a proportion of 
patients. Donor engraftment was assessed by fluores-
cence in situ hybridisation (FISH) or variable tandem 
repeat polymorphism analysis by polymerase chain 
reaction (PCR). Full donor chimerism was defined as 
the presence of >95% donor cells by FISH or PCR. 
Donor lymphocytes were administered in a number of 
patients either as management of mixed hemopoietic 
chimerism or at disease relapse.
Outcomes and statistical analysis:
Long term follow up data is available on all patients. 
The median duration of follow-up in alive patients is 
31 months (range 6-105 months) and 34 patients were 
transplanted three years or more prior to the final data 
analysis. Two patients died before day 28 and were 
excluded from analysis of engraftment kinetics. The 
main end-points of the study were OS, DFS and time 
to relapse. Survival curves were constructed using 
the method of Kaplan and Meier19 and the log-rank 
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test20 was used to assess differences between groups. 
OS was measured from the time of transplantation 
until death from any cause; DFS was measured from 
transplantation until disease-relapse or death. Patients 
still alive at the time of the analysis were censored at 
date of last follow-up. Time to relapse was calculated 
from date of transplant to date of first relapse; patients 
who did not relapse were censored at either date of 
death or date of last follow-up as appropriate. Minor 
end-points were transplant-related mortality (TRM) at 
100 days and one year post-transplant and acute and 
chronic GvHD. TRM was defined as death in CR or 
death related to transplantation where it was not pos-
sible to assess disease status prior to death. Univari-
ate analyses of the association of various clinical risk 
factors (sex, age, disease status, cytogenetics, donor 
type and GvHD) with these post-transplantation out-
comes were calculated using univariate Cox regres-
sion analyses21. Multivariate analyses were performed 
using forward stepwise Cox proportional hazards re-
gression to determine independent predictors of OS, 
DFS, TRM and time to relapse in patients allografted 
for AML. All factors found to have a p value of <0.1 
in the previous univariate analysis were included in 
a multivariate analysis. Tests of significance were 
two-sided and had a significance level of 0.05 or less. 
Patients who died from other causes were censored 
at the time of death. Data were analyzed using the 
statistical software SAS (SAS Institute, SAS Circle, 
North Carolina, USA). For OS and DFS, risk factors 
found to be significant in multivariate analyses were 
used to generate a risk score for each outcome. These 
risk scores are variables free from subjective interpre-
tation providing a more clear-cut basis for advising on 
an individual patient basis.
RESULTS
Engraftment and Chimerism 
65 of the 67 patients engrafted. The median time 
to acquisition of an absolute neutrophil count > 0.5 
x 109/l was 14 days (range 7-25 days). The median 
time to acquisition of a platelet count > 50 x 109/l was 
16 days (range 7-66 days). Primary graft failure was 
documented in two patients-both recipients of unre-
lated grafts. The results of day 90 chimerism studies 
are available for 62 patients. 46 patients demonstrated 
full donor chimerism in whole blood and 40 in the T 
cell fraction. 13 patients demonstrated mixed chime-
rism in whole blood and 22 mixed chimerism in the T 
cell fraction at day 90. 
Overall survival
At the time of analysis, 34 (50%) patients were alive. 
The 3-year probability of OS for the entire group 
of patients was 47% (95% CI, 38% to 55%) . The 3 
year OS for patients transplanted in CR1 or CR2/CR3 
was 50% (95% CI, 38% to 62%) and 49% (95% CI, 
34% to 61%) respectively compared to 17% (95% CI, 
3% to 40%) for patients with relapsed/refractory dis-
ease . The 3 year OS for patients with intermediate risk 
cytogenetics was 53% (95% CI, 42% to 62%) com-
pared with 31% (95% CI, 17% to 45%) for patients 
with adverse risk cytogenetics . There was no impact 
of patient age on OS. Patients aged under 60 years 
had a 3 year OS rate (48%) comparable to patients 
60 years old or over (46%) (p = 0.31). No difference 
was noted in outcome between patients receiving an 
allograft from a volunteer unrelated donor and those 
using a sibling donor (p = 0.39). However in patients 
transplanted using an unrelated donor the presence 
of an antigenic mismatch at a class 1 or II allele was 
associated with an inferior outcome compared with 
patients receiving a transplant from a donor with no 
detectable HLA disparity (3 year OS 11% v 58%, 
p < 0.001) . Alemtuzumab dose did not impact on the 
rate of overall survival. 
In univariate analysis, adverse risk cytogenetics 
and active disease at the time of transplant were asso-
ciated with a lower OS. Multivariate analyses showed 
both relapsed/refractory disease (HR, 1.4; 95% CI, 
1.1-1.9; p = 0.002) and adverse-risk cytogenetics (HR, 
2.1; 95% CI, 1.4-3.3; p = 0.03) to be associated with a 
lower OS (Table 2a). In addition, for the subgroup of 
patients transplanted using an unrelated donor, multi-
variate analysis showed the use of a mismatched do-
nor to be associated with poorer OS (HR, 2.8; 95% CI, 
1.5-5.3; p = 0.001) (Table 2a). 
Disease free survival
The 3-year probability of DFS for the whole group 
was 43% (95% CI, 35%-52%). The 3 year DFS for 
patients transplanted in CR1 or CR2/CR3 was 49% 
and 40% respectively. The 3 year DFS for patients 
with intermediate risk cytogenetics was 49% (95% 
CI, 39% to 59%) compared to 28% (95% CI, 15% to 
43%) for patients with adverse risk cytogenetics. The 
three year DFS for patients transplanted using a mo-
lecularly matched unrelated donor was 50% (95% CI, 
36%-63%) compared with 11% (95% CI, 2%-29%) 
for patients transplanted using a mismatched unre-
lated donor.
In univariate analysis, the variables associated 
with a lower DFS were relapsed/refractory status at 
the time of transplant and adverse risk cytogenetics. 
Multivariate analysis demonstrated that relapsed/
refractory disease status (HR, 2.6; 95% CI, 1.5-4.7; 
p = 0.001) and adverse-risk cytogenetics (HR, 1.9; 
95% CI, 1.2-2.9; p = 0.007) were associated with a 
lower DFS (Table 2b). Patients transplanted using a 
mismatched unrelated donor had a lower DFS (HR, 
2.2; 95% CI, 1.2-4.2; p = 0.01) (Table 2b).
Disease relapse
Disease relapse occurred in 20 (29%) patients and 
represented the major cause of patient death (49% 
of all deaths). The median time to relapse was 6.5 
months (interquartile range, 4-10 months). 45% of 
patients who relapsed did so in the first 6 months fol-
lowing transplantation. 82% of patients destined to 
relapse had done so within one year post-transplant. 
31% (95% CI, 22% to 42%) of patients with inter-
mediate risk cytogenetics transplanted in remission 
relapsed compared to 64% (95% CI, 39% to 88%) of 
patients with adverse risk cytogenetics transplanted in 
remission (P = 0.01). The 1-year relapse risk for those 
transplanted in CR was 33% (95% CI, 25%-40%) 
compared to 59% (95% CI, 35%-85%) for those with 
relapsed/refractory status. There was no difference in 
relapse risk between recipients of sibling and unrelat-
ed donor transplants (p = 0.77). Development of acute 
or chronic GVHD did not influence relapse rates (p 
= 0.6 and p = 0.2 respectively). Alemtuzumab dose 
did not impact on the incidence of disease relapse 
(p = 0.16). 9 patients received DLI as treatment for 
mixed chimerism (n = 3) or disease relapse (n = 6). 7 
patients who received DLI died of relapsed disease. 
In univariate analyses the factors associated 
with disease relapse were adverse-risk cytogenetics 
(p = 0.03) and the presence of relapsed/refractory dis-
ease at the time of transplant. In multivariate analysis, 
the only risk factor associated with disease relapse 
was relapsed/refractory disease (HR, 3.0; 95% CI, 
1.4-6.5; p = 0.004) (Table 2c).
GVHD and Transplant Related Mortality
19 patients (30%) developed Grade II-IV acute GVHD. 
5 (7%) patients developed Grade III-IV acute GVHD. 
14 patients (21%) developed chronic GVHD. 11 pa-
tients (16%) developed limited chronic GVHD and 
Table 2a. Univariate and multivariate analyses of donor and patient factors predicting overall survival.
Univariate Analysis Multivariate Analysis
HR P HR 95% CI P
Refractory/Relapsed Disease 2.5 < 0.001 1.4 1.1-1.9 0.002
Adverse Cytogenetics 2.2 < 0.001 2.1 1.4-3.3 0.03
Mismatched unrelated donor 3.1 < 0.001 2.8 1.5-5.3 0.001
Table 2b. Univariate and multivariate analyses of donor and patient factors predicting disease free survival.
Univariate Analysis Multivariate Analysis
HR P HR 95% CI P
Refractory/Relapsed Disease 3.1 < 0.001 2.6 1.5-4.7 0.001
Adverse Cytogenetics 2.1 0.002 1.9 1.2-2.9 0.007
Mismatched unrelated donor 2.4 0.004 2.2 1.2-4.2 0.01
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3(4%) extensive chronic GVHD. Alemtuzumab dose 
did not impact on the incidence of acute or chronic 
GVHD (p = 0.1 and 0.5 respectively).
The day 100 TRM was 10% (95% CI, 7%-16%) 
and 17% (95% CI, 12%-24%) at one year post-trans-
plant. The day 100 TRM in patients undergoing trans-
plantation from a sibling donor was 7% compared 
with 13% from an unrelated donor (p = 0.28). The 
day 100 TRM in patients aged under 60 years was 
9% compared to 16% in patients 60 years old or over 
(p = 0.18). The day 100 day TRM in relapsed/refrac-
tory patients was significantly higher than in patients 
transplanted in CR (25% v 9%). Univariate analysis 
showed relapsed/refractory disease to be the only 
variable associated with higher day-100 mortality 
(HR, 2.4; p = 0.02) (Table 2d). In volunteer unrelated 
donors, univariate analysis demonstrated that the use 
of a mismatched unrelated donor was the only vari-
able associated with an increased day 100 TRM (HR, 
11.5, p = 0.002) (Table 2d). 
Outcome modelling
A model predicting survival was constructed using sta-
tus at transplant, cytogenetic status and donor match 
(sibling or molecularly matched unrelated donor ver-
sus mismatched unrelated donor) to provide a mea-
sure of prognostication in newly diagnosed patients. 
The risk score for each patient comprised the sum of 
the risk factors using the following criteria: 0 for CR 
Table 2c. Univariate and multivariate analyses of donor and patient factors predicting relapse risk.
Univariate Analysis Multivariate Analysis
HR P HR 95% CI P
Refractory/Relapsed Disease 3.0 0.004 3.0 1.4-6.5 0.004
Adverse Cytogenetics 2.0 0.03 - - -
Table 2d. Univariate analysis of donor and patient factors predicting 100 day transplant related mortality.
Univariate Analysis
HR P
Refractory/Relapsed Disease 2.4 0.02
Mismatched unrelated donor 11.5 0.002
Table 3. 3 year probability of OS and DFS for patients with AML after RIC allogeneic transplantation according to prog-
nostic score. Risk was assigned according to the following model: Disease status at transplant: CR = 0, relapsed/refractory 
disease = 1. Presentation karyotype: intermediate risk cytogenetics = 0, adverse risk = 1. Patient:donor HLA disparity: HLA 
matched sibling or molecularly matched unrelated donor = 0, mismatched unrelated donor = 1.
Risk Score Number of Patients Probability of outcome at 3 years (%)
OS DFS
0 41 60 56
1 15 36 34
2-3 6 9 9
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disease and 1 for relapsed/refractory disease, 0 for in-
termediate risk cytogenetics and 1 for adverse cytoge-
netics, 0 for “matched” donor and 1 for “mismatched” 
donor. The lowest possible score on this scale is 0, 
corresponding to a CR patient with intermediate risk 
cytogenetics and a matched sibling or unrelated do-
nor. The impact of the prognostic score on outcome is 
documented in Table 3. 
DISCUSSION
This study confirms the ability of alemtuzumab based 
RIC allografts to deliver long term disease free sur-
vival, with a low risk of acute or chronic GVHD, in a 
substantial proportion of older patients with high risk 
AML. We have identified a number of host and donor 
characteristics associated with a good outcome using 
this T cell depleted reduced intensity regimen. As a 
contrary it has been possible to define a group of pa-
tients with AML who have a relatively poor outcome 
using an alemtuzumab based RIC regimen for whom 
novel reduced intensity transplant strategies will be 
required.
In multivariate analysis the major determinants 
of long term survival are disease status at the time 
of transplantation, presentation cytogenetics and the 
degree of donor:host HLA disparity. Importantly, and 
in stark contrast to myeloablative transplants in AML, 
no impact of age was seen on outcome and it may be 
that this regimen can be safely extended to patients 
older than 65 providing they have a suitably matched 
donor4,5. The incorporation of these factors into a 
prognostic score assists in risk stratification aswell 
as the identification of patients with a poor outcome 
who would be suitable for future Phase II clinical 
studies. It is important to note that whilst our results 
report outcomes which compare favourably with con-
ventional chemotherapy the extent, if any, to which 
patient selection has biased these results is difficult 
to determine. For this reason the ongoing donor v no 
donor analyses planned in a number of international 
studies will be of importance. 
Our observation that the development of GVHD 
did not correlate with overall survival or relapse risk 
contrasts with the results of previous studies using 
a T replete RIC protocol in which the development 
of chronic GVHD was associated with an improved 
outcome24-26. A similar lack of correlation between 
GVHD and relapse risk has been reported using an 
alemtuzumab based reduced intensity regimen in Non-
Hodgkin’s lymphoma27. However our data clearly do 
not exclude the presence of a clinically significant T 
cell mediated GVL effect occurring in the context of 
sub-clinical GVHD. Alternatively the existence of an 
anti-tumor response mediated by a cellular compart-
ment which is not susceptible to depletion by alemtu-
zumab is possible. Consequently detailed analysis of 
the impact of alemtuzumab on the numbers and func-
tion of NK cells, T regulatory cells and other potential 
cellular effectors which may mediate a GVL effect 
post transplant is required. An alternative explanation 
for the apparent dissociation of GVHD and GVL in 
these patients is the possibility that CD52 is expressed 
on leukemic stem cells and that alemtuzumab has a 
direct anti-tumor effect similar to that postulated for 
gemtuzumab ozogamicin28.
This study identifies a population of patients with 
AML whose outcome with an alemtuzumab based al-
lograft is less favourable. It has previously been dem-
onstrated that remission status is a critical predictor 
of relapse and survival after both myeloablative and 
reduced intensity allografts for AML9,29-32. However 
although cytogenetic status has been shown to be 
an important predictor of outcome in patients trans-
planted using a myeloablative regimen the impact of 
presentation karyotype has not previously been exam-
ined in patients undergoing a reduced intensity trans-
plant33. In this study OS was significantly decreased 
in patients with adverse risk cytogenetics at presenta-
tion. Despite this the 35% 3 year OS in patients with 
adverse risk cytogenetics who were transplanted in re-
mission remains encouraging given the poor outcome 
of this group if treated with chemotherapy alone. 
Strategies which might decrease the risk of disease re-
currence post-transplant include reducing the dose of 
pre-transplant alemtuzumab or decreasing the inten-
sity of post-transplant immunosuppression by modi-
fying the dose or duration of cyclosporin administered 
post-transplant34-36. Alternatively, since remission sta-
tus appears to be a major determinant of relapse risk, 
the role of additional cytoreductive therapy pre-trans-
plant should be studied16,37. Both of these approaches 
are embodied in the FLAMSA regimen developed by 
Kolb and colleagues38,39 and the impact of these strate-
gies should be further studied in the population of pa-
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tients we have identified to be at a high risk of relapse 
in this study. 
The role of adjunctive DLI in restoring a GVL ef-
fect and thereby decreasing relapse risk after T cell 
depleted RIC allografts remains unexplored40. In this 
study only small numbers of patients received DLI and 
it is not possible to comment on its potential benefit. 
One of the major limitations of either prophylactic or 
pre-emptive DLI after RIC allografts is the high rate 
of severe acute GVHD associated with even modest 
lymphocyte doses in the first year post-transplant40,41. 
Since the great majority of patients destined to re-
lapse after a T depleted RIC allograft for AML will 
do so within the first year post-transplant, interven-
tions which postpone relapse and allow DLI to be ad-
ministered at a later time point may be of benefit. We 
have previously demonstrated that adjunctive post-
transplant imatinib can effectively manipulate the ki-
netics of disease recurrence and thereby postpone the 
requirement for early DLI42. Similar combinations of 
leukemic specific therapy should be explored after T 
cell depleted reduced intensity allografts in AML and 
the tolerability and activity of demethylating agents 
or flt3 inhibitors (in FLT3 itd positive AML) or will 
be of interest. 
Comparable outcomes have previously been re-
ported with sibling and unrelated donors in patients 
transplanted using a reduced intensity regimen14,43. 
Indeed it has been suggested that there may be a ben-
efit associated with the use of unrelated donors conse-
quent upon a lower relapse rate9. In this study whilst 
we confirm equivalence of outcome between recipi-
ents of HLA identical sibling donors and molecularly 
matched unrelated donors we have identified a distinct 
adverse effect on survival in patients transplanted us-
ing a molecularly mismatched unrelated donor. Since 
the majority of older patients will not have a matched 
sibling donor who is fit to donate stem cells most 
reduced intensity transplants in this population are 
likely to be performed using an unrelated donor. The 
adverse impact of HLA mismatch observed in this se-
ries will, if confirmed, limit the availability of suit-
ably matched unrelated donors and attention will have 
to be given to alternative stem cell sources such as 
umbilical cord blood. In this context the encouraging 
results recently reported in patients with double cord 
blood transplants in older patients with high risk AML 
are of importance44-46.
In summary this study has delineated a substan-
tial population of older patients with AML in whom 
a T cell depleted reduced intensity allograft can de-
liver encouraging long term disease free survival with 
modest rates of GVHD. Prospective studies and a 
higher number of patients will be required to confirm 
whether transplantation is superior to chemotherapy 
in this group of patients. At the same time it is clear 
that a number of patient and donor characteristics can 
be used to identify patients in whom outcome with a 
T depleted RIC allograft is poor and for whom new 
transplant strategies are required.
ΠΕΡΙΛΗΨΗ: Οι αλλογενείς μεταμοσχεύσεις με μειωμένης έντασης χημειοθεραπεία (reduced intensity conditioning) επι-
τρέπουν την επέκταση μιας ενδεχομένως θεραπευτικής επίδρασης του μοσχεύματος εναντίον της λευχαιμίας σε ασθενείς 
προχωρημένης ηλικίας με οξεία μυελογενή λευχαιμία (AML) των οποίων η επιβίωση με τη χημειοθεραπεία θα ήταν φτωχή. 
Η εκλεκτική αφαίρεση Τ κυττάρων με alemtuzumab μειώνει τον κίνδυνο σοβαρού GVHD (graft versus host disease) αλλά 
μπορεί να διατηρήσει την αντι-λευχαιμική δραστηριότητα του μοσχεύματος. Σε αυτή τη μελέτη έχουμε αναλύσει τους 
Αλλογενείς μεταμοσχεύσεις μυελού με μειωμένης έντασης χημειοθεραπεία  
(reduced intensity conditioning) και εκλεκτική αφαίρεση Τ λεμφοκυττάρων:  
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